Risk Factors Update Summary
- Completed a registered direct offering of 11,111,111 shares for gross proceeds of approximately $15.0 million.
- Delayed the initiation of the ODYSSEY trial by one quarter due to FDA draft guidance.
- Increased federal net operating loss from approximately $216 million to $225 million.
- Increased state net operating loss from approximately $78 million to $89 million.
- Extended the expiration dates of state NOL carryforwards from 2031 to 2034.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1539029&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.